Key points are not available for this paper at this time.
REMISSION after cytotoxic therapy in acute nonlymphocytic leukemia is thought to result from selective destruction of leukemic cells and repopulation of the marrow by normal stem cells. This postulate is supported by the restoration of a normal karyotype in marrow cells and cultured myeloid colonies after chemotherapy.1 2 3 In addition, in five patients with acute nonlymphocytic leukemia who were heterozygous for glucose-6-phosphate dehydrogenase, only a single enzyme type was found in the leukemic blast cells on initial presentation, but when the patients entered clinical remission, a normal double-enzyme phenotype was observed in mature granulocytes and their precursors.4 5 6 These findings indicated that . . .
Jacobson et al. (Thu,) studied this question.